Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 2
2013 2
2014 2
2015 2
2016 1
2018 1
2019 1
2020 3
2022 2
2023 1
2024 3
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean sara pezzotti (5 results)?
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Free article. Clinical Trial.
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients.
Morabito F, Martino EA, Galli M, Offidani M, Zambello R, Bringhen S, Giuliani N, Califano C, Brunori M, Gagliardi A, Sgherza N, Quinto AM, Barilà G, Belotti A, Cerchione C, Casaluci GM, Fontana R, Bongarzoni V, Tarantini G, Derudas D, Patriarca F, Gozzetti A, Sementa A, Antonioli E, Rago A, Lotti F, De Magistris C, Petrucci MT, Pettine L, Bolli N, Conticello C, Zamagni E, Palmieri S, Musso M, Mele A, Della Pepa R, Vigna E, Bruzzese A, Fazio F, Mina R, Paris L, Vincelli ID, Farina G, Cangialosi C, Mancuso K, Falcone AP, Mele G, Sica A, Morè S, Reddiconto G, Tripepi G, D'Arrigo G, Barbieri E, Quaresima M, Cartia CS, Pezzatti S, Marcatti M, Farina F, Cafro A, Palumbo M, Masoni V, Ferretti VV, Di Raimondo F, Musto P, Neri A, Mangiacavalli S, Gentile M. Morabito F, et al. Among authors: pezzatti s. Eur J Haematol. 2025 Jul;115(1):16-28. doi: 10.1111/ejh.14413. Epub 2025 Mar 19. Eur J Haematol. 2025. PMID: 40103518 Free PMC article.
Impact of the Addition of Daratumumab to the Standard Bortezomib-Thalidomide-Dexamethasone Regimen on Hematopoietic Stem Cell Mobilization and Collection, Post-Transplant Engraftment and Infectious Complications: A Case-Control Multicentre Real-Life Analysis.
Cavallaro G, Paris L, Stefanoni P, Pavoni C, Mangiacavalli S, Cartia CS, Pompa A, Cafro AM, Pioltelli ML, Pezzatti S, Crippa S, Rambaldi A, Galli M. Cavallaro G, et al. Among authors: pezzatti s. Mediterr J Hematol Infect Dis. 2024 May 1;16(1):e2024049. doi: 10.4084/MJHID.2024.049. eCollection 2024. Mediterr J Hematol Infect Dis. 2024. PMID: 38882460 Free PMC article. No abstract available.
Feasibility and effectiveness of the prolonged use of eltrombopag in addition to immunosuppression in patients with acquired aplastic anemia: a single-center real-life experience.
Carpenedo M, Zappaterra A, Del Castello L, Ferrari B, Cotilli G, Bernasconi DP, Pezzatti S, Sacco F, Borin L, Carrer A, Verga L, Brioschi F. Carpenedo M, et al. Among authors: pezzatti s. Platelets. 2024 Dec;35(1):2415483. doi: 10.1080/09537104.2024.2415483. Epub 2024 Oct 16. Platelets. 2024. PMID: 39641636 Free article.
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials.
D'Agostino M, De Paoli L, Conticello C, Offidani M, Ria R, Petrucci MT, Spada S, Marcatti M, Catalano L, Gilestro M, Guglielmelli T, Baldini L, Gamberi B, Rizzi R, De Sabbata G, Di Renzo N, Patriarca F, Pezzatti S, Siniscalchi A, Ribolla R, Palumbo A, Montefusco V, Nagler A, Boccadoro M, Gay F. D'Agostino M, et al. Among authors: pezzatti s. Crit Rev Oncol Hematol. 2018 Dec;132:9-16. doi: 10.1016/j.critrevonc.2018.09.008. Epub 2018 Sep 14. Crit Rev Oncol Hematol. 2018. PMID: 30447931 Free article. Review.
Autologous transplantation and maintenance therapy in multiple myeloma.
Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, Pezzatti S, Caravita T, Cerrato C, Ribakovsky E, Genuardi M, Cafro A, Marcatti M, Catalano L, Offidani M, Carella AM, Zamagni E, Patriarca F, Musto P, Evangelista A, Ciccone G, Omedé P, Crippa C, Corradini P, Nagler A, Boccadoro M, Cavo M. Palumbo A, et al. Among authors: pezzatti s. N Engl J Med. 2014 Sep 4;371(10):895-905. doi: 10.1056/NEJMoa1402888. N Engl J Med. 2014. PMID: 25184862 Free article. Clinical Trial.
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, Cavalli M, Stanevsky A, Corradini P, Pezzatti S, Patriarca F, Cavo M, Peccatori J, Catalano L, Carella AM, Cafro AM, Siniscalchi A, Crippa C, Petrucci MT, Yehuda DB, Beggiato E, Di Toritto TC, Boccadoro M, Nagler A, Palumbo A. Larocca A, et al. Among authors: pezzatti s. Blood. 2012 Jan 26;119(4):933-9; quiz 1093. doi: 10.1182/blood-2011-03-344333. Epub 2011 Aug 11. Blood. 2012. PMID: 21835953 Free article. Clinical Trial.
18 results